Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 22, 2019
DaVita's (DVA, $59.31) Q2 operating income outlook comes in higher than expected

DaVita's (DVA, $59.31) Q2 operating income outlook comes in higher than expected

Shares of DaVita surged more than +5% in premarket trading Monday, following news of the company’s second-quarter operating income guidance exceeding analysts’ expectations.

The healthcare company reported its projection for second-quarter operating income between $460 million and $465 million - a range that is substantially higher than the FactSet consensus of $398 million. 

For the full-year, the company increased its adjusted operating income guidance to between $1.64 billion and $1.70 billion, from its prior forecast of a range of $1.54 billion to $1.64 billion. 

The news comes ahead of DaVita’s modified Dutch auction tender offer on up to $1.2 billion of its common stock. The auction, priced between $53.50  and $61.50 per share, will start on Monday and continue until August 16 midnight. 

 

 

 

 

Related Ticker: DVA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


DVA's RSI Indicator recovers from oversold territory

The RSI Oscillator for DVA moved out of oversold territory on August 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 18 of the 26 cases the stock moved higher. This puts the odds of a move higher at 69%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 02, 2026. You may want to consider a long position or call options on DVA as a result. In 57 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

The Moving Average Convergence Divergence (MACD) for DVA just turned positive on August 26, 2026. Looking at past instances where DVA's MACD turned positive, the stock continued to rise in 29 of 43 cases over the following month. The odds of a continued upward trend are 67%.

Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 237 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 64 cases where DVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

DVA broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DVA entered a downward trend on September 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. DVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (91.743) is normal, around the industry mean (208.357). P/E Ratio (15.581) is within average values for comparable stocks, (175.235). Projected Growth (PEG Ratio) (0.450) is also within normal values, averaging (2.492). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.85B. The market cap for tickers in the group ranges from 20.9K to 92.6B. HCA holds the highest valuation in this group at 92.6B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 41%. STLN experienced the highest price growth at 13%, while NIVF experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 175%. For the same stocks of the Industry, the average monthly volume growth was 144% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 45
Price Growth Rating: 51
SMR Rating: 66
Profit Risk Rating: 87
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
DVA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of integrated dialysis services for patients suffering from chronic kidney failure

Industry HospitalNursingManagement

Profile
Details
Industry
Medical Or Nursing Services
Address
2000 16th Street
Phone
+1 720 631-2100
Employees
78000
Web
https://www.davita.com
Interact to see
Advertisement
Shares of NSA stock surged roughly 27% in premarket trading after the company agreed to be acquired by Public Storage in an all-stock transaction valued at about $10.5 billion. The deal values National Storage Affiliates at an implied price of about $41.68 per share, representing a substantial premium to its prior closing price near the low-$30s.
Shares of NBIS jumped roughly 12% in premarket trading after a sharp rally in the prior regular session. The latest leg of the price rally follows news of a multibillion‑dollar, long‑term AI infrastructure agreement with Meta Platforms that expands Nebius’s cloud capacity commitments.
Micron Technology’s common stock MU (MU) rose 5.13% in the latest completed session, closing at 426.13 dollars versus 405.35 dollars previously. The move appears driven by continued enthusiasm around Micron’s role as a key memory supplier to artificial intelligence and data center markets, supporting an earnings-driven re‑rating of the stock.
IperionX Limited (IPX) is down about 15.57% in early trading on March 16, with shares recently changing hands near 29.44 dollars versus a previous close of 34.87 dollars. The drop extends a post‑earnings selloff after the company’s March 12 results highlighted continued losses and substantial funding needs to scale its titanium operations.
Shares of CTMX surged roughly 56% in the latest session, staging a sharp intraday price rally from the prior close. The move appears driven by earnings-related positioning and growing optimism around CytomX’s PROBODY therapeutic platform and late‑stage oncology pipeline.
Hyperliquid Strategies Inc (PURR) shares jumped about 15% in the latest session, extending a multi-week price rally tied to digital-asset exposure. The move comes as traders bid up proxy plays on the Hyperliquid ecosystem and HYPE token, with renewed risk appetite in crypto-related assets.
VIA fell over 11% today, extending a slide that began last week; the stock has been under pressure since trading around the high‑teens and low‑$20s, well below its $46 IPO price.
LAES fell more than 19% today as the market digested a $125 million registered direct offering of 30.4 million new shares (or pre‑funded warrants) plus warrants for up to 60.8 million additional shares, all priced at $4.11 per unit.
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
DaVita's (DVA, $59.31) Q2 operating income outlook comes in higher than expected